Artivion (AORT) Stock Forecast & Price Target

Artivion is supported by strong underlying demand in its core aortic and mechanical-valve franchises, as 3Q26 revenue rose 9% to $123.8 million and adjusted EBITDA beat expectations at $22.5 million, while management also tightened 2026 revenue guidance to +8-10% and kept EBITDA near $96 million. Its outlook is strengthened by a product-cycle inflection from AMDS and NEXUS, with sequential AMDS improvement, January 1, 2027 NEXUS launch preparation, and expanding manufacturing and inventory positioning both platforms for growth. The company also benefits from On-X’s 13% growth, improving supply, and a portfolio that offers high-margin, long-duration opportunities across North America and international markets, supporting continued EBITDA margin expansion.

Artivion is facing a deteriorating fundamental profile as gross margin fell to 61.4% in the quarter, down about 420 bps year over year, while adjusted EBITDA declined 8% to $22.5 mln and the margin compressed to 18.2% amid Endospan costs, product-mix pressure, and early ramp expenses at the new On-X and NEXUS facilities. Cash fell to $48.4 mln from $77.3 mln in 2Q26 and net leverage reached 3.5x after a $25 mln milestone payment in July, underscoring a weaker balance sheet and limited near-term financial flexibility. Its outlook is further restrained by heavy dependence on tissue preservation and BioGlue, plus regulatory, donor-supply, and international exposure, while management’s expectation for more meaningful free cash flow improvement only over 2027 leaves execution risk elevated.